Last 7 days
-1.3%
Last 30 days
-4.7%
Last 90 days
-0.8%
Trailing 12 Months
49.9%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
BGNE | 322.8B | 1.6B | -3.71% | 80.48% | -168.39 | 207.32 | 77.54% | 1.62% |
ABBV | 285.4B | 56.7B | -14.98% | -6.85% | 24.12 | 4.92 | 0.03% | -39.22% |
REGN | 87.6B | 12.4B | -6.81% | 6.09% | 20.2 | 7.2 | -25.07% | -47.28% |
VRTX | 85.0B | 9.2B | 2.07% | 22.38% | 26.07 | 9.23 | 15.86% | 32.99% |
ALNY | 23.4B | 1.0B | -4.69% | 49.89% | -21.96 | 22.55 | 22.88% | -19.27% |
SRPT | 11.8B | 975.7M | 3.71% | 78.87% | -10.59 | 12.11 | 27.41% | -212.78% |
UTHR | 9.7B | 2.0B | -8.21% | -7.77% | 13.31 | 4.89 | 12.05% | 52.86% |
MID-CAP | ||||||||
MDGL | 5.2B | 504.0K | -7.29% | 316.43% | -16.55 | 2.5K | -66.53% | -27.52% |
RARE | 3.5B | 363.3M | 17.72% | 8.70% | -4.94 | 9.63 | 3.39% | -55.81% |
BPMC | 3.5B | 204.6M | 17.81% | 4.32% | -6 | 17.05 | -7.52% | 10.65% |
MRTX | 2.2B | 18.9M | -10.74% | -34.21% | -3.03 | 118.36 | - | -16.17% |
SMALL-CAP | ||||||||
CYTK | 3.5B | - | 0.59% | -4.18% | -8.22 | 37.46 | 34.30% | -67.22% |
CPRX | 1.2B | 256.5M | -28.21% | 63.82% | 12.26 | 4.75 | 66.85% | 120.61% |
MGNX | 315.4M | 165.3M | -25.22% | 48.69% | -3.45 | 1.91 | 130.70% | 57.97% |
CRBP | 41.8M | 881.7K | 29.00% | 3203.36% | -0.83 | 19.11 | -77.61% | -29.84% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 8.0% | 1,037,418,000 | 960,918,000 | 884,245,000 | 879,980,000 | 844,287,000 |
S&GA Expenses | 3.2% | 770,658,000 | 746,696,000 | 652,912,000 | 628,251,000 | - |
R&D Expenses | 3.9% | 883,015,000 | 850,026,000 | 799,227,000 | 776,150,000 | - |
EBITDA | 5.1% | -926,557,000 | -975,871,000 | -773,788,000 | -694,931,000 | - |
EBITDA Margin | 12.1% | -0.89 | -1.02 | -0.88 | -0.79 | - |
Earnings Before Taxes | 4.5% | -1,126,993,000 | -1,180,274,000 | -978,567,000 | -892,225,000 | - |
EBT Margin | 11.6% | -1.09 | -1.23 | -1.11 | -1.01 | - |
Interest Expenses | -4.2% | 155,968,000 | 162,871,000 | 162,061,000 | 152,868,000 | - |
Net Income | 4.3% | -1,131,156,000 | -1,182,123,000 | -980,717,000 | -892,874,000 | - |
Net Income Margin | 11.4% | -1.09 | -1.23 | -1.11 | -1.01 | - |
Free Cahsflow | 2.9% | -613,333,000 | -631,747,000 | -660,051,000 | -654,279,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -4.4% | 3,392 | 3,546 | 3,535 | 3,330 | 3,434 |
Current Assets | -5.6% | 2,541 | 2,692 | 2,691 | 2,472 | 2,590 |
Cash Equivalents | -22.4% | 672 | 866 | 1,073 | 576 | 534 |
Inventory | 2.3% | 132 | 129 | 115 | 89.00 | 79.00 |
Net PPE | -0.1% | 523 | 523 | 515 | 508 | 504 |
Liabilities | -1.4% | 3,651 | 3,705 | 3,603 | 3,154 | 3,032 |
Current Liabilities | -12.3% | 673 | 768 | 773 | 658 | 606 |
Long Term Debt | 0.1% | 678 | 677 | - | - | - |
Shareholder's Equity | -63.8% | -259 | -158 | 176 | 401 | - |
Retained Earnings | -2.7% | -6,743 | -6,569 | -6,361 | -5,955 | -5,678 |
Additional Paid-In Capital | 1.0% | 6,522 | 6,455 | 6,337 | 6,173 | 6,117 |
Shares Outstanding | 0.3% | 124 | 124 | 123 | 121 | 121 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | 0.9% | -536 | -541 | -559 | -578 | -577 |
Share Based Compensation | 4.6% | 241 | 231 | 232 | 138 | 139 |
Cashflow From Investing | 42.0% | 241 | 169 | -104 | -506 | -492 |
Cashflow From Financing | 2.7% | 437 | 426 | 655 | 931 | 1,231 |
100%
43.5%
18.5%
Y-axis is the maximum loss one would have experienced if Alnylam Pharmaceuticals was unfortunately bought at previous high price.
20.2%
15.8%
13.5%
11.3%
FIve years rolling returns for Alnylam Pharmaceuticals.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-23 | Front Row Advisors LLC | new | - | 3,000 | 3,000 | -% |
2023-05-23 | Toroso Investments, LLC | added | 77.84 | 506,000 | 1,520,000 | 0.03% |
2023-05-22 | AMERIPRISE FINANCIAL INC | added | 328 | 29,440,000 | 40,699,000 | 0.01% |
2023-05-18 | INTERNATIONAL BIOTECHNOLOGY TRUST PLC | added | 22.63 | 314,888 | 9,333,050 | 2.60% |
2023-05-18 | CENTAURUS FINANCIAL, INC. | added | 1.48 | -25,000 | 151,000 | 0.01% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -4.27 | -7,099,000 | 29,665,000 | 0.04% |
2023-05-18 | JPMORGAN CHASE & CO | reduced | -1.05 | -123,361,000 | 619,936,000 | 0.08% |
2023-05-17 | Sunbelt Securities, Inc. | new | - | 3,512 | 3,512 | -% |
2023-05-17 | Thrivent Financial for Lutherans | unchanged | - | -39,000 | 210,000 | -% |
2023-05-17 | Advisory Services Network, LLC | reduced | -66.99 | -141,848 | 54,688 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | price t rowe associates inc /md/ | 3.3% | 4,074,144 | SC 13G/A | |
Feb 13, 2023 | capital world investors | 13.5% | 16,593,958 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.35% | 11,507,116 | SC 13G/A | |
Feb 06, 2023 | wellington management group llp | 5.09% | 6,261,642 | SC 13G/A | |
Jan 31, 2023 | blackrock inc. | 7.0% | 8,665,702 | SC 13G/A | |
Jan 19, 2023 | baillie gifford & co | 7.65% | 9,407,871 | SC 13G/A | |
Sep 09, 2022 | capital world investors | 10.7% | 12,816,777 | SC 13G | |
Feb 14, 2022 | price t rowe associates inc /md/ | 5.4% | 6,535,368 | SC 13G | |
Feb 09, 2022 | vanguard group inc | 8.95% | 10,702,771 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
May 23, 2023 | 8-K | Current Report | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading | |
May 19, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-04-28 | Garg Pushkal | sold | -488,595 | 199 | -2,455 | cmo & evp dev & med affairs |
2023-04-27 | Tanguler Tolga | sold | -287,215 | 194 | -1,476 | evp, chief commercial officer |
2023-04-27 | Vaishnaw Akshay | sold | -465,464 | 194 | -2,392 | president |
2023-04-27 | Greenstreet Yvonne | sold | -1,481,810 | 194 | -7,615 | chief executive officer |
2023-04-27 | Garg Pushkal | sold | -357,855 | 194 | -1,839 | cmo & evp dev & med affairs |
2023-04-27 | Poulton Jeffrey V. | sold | -190,113 | 194 | -977 | evp, chief financial officer |
2023-04-26 | Poulton Jeffrey V. | acquired | - | - | 3,277 | evp, chief financial officer |
2023-04-26 | Tanguler Tolga | acquired | - | - | 3,277 | evp, chief commercial officer |
2023-04-26 | Garg Pushkal | acquired | - | - | 4,294 | cmo & evp dev & med affairs |
2023-04-26 | Vaishnaw Akshay | acquired | - | - | 5,312 | president |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenues: | ||
Total revenues | $ 319,290 | $ 213,259 |
Operating costs and expenses: | ||
Cost of goods sold | 41,432 | 23,457 |
Cost of collaborations and royalties | 13,437 | 12,170 |
Research and development | 230,569 | 169,893 |
Selling, general and administrative | 183,659 | 154,471 |
Total operating costs and expenses | 469,097 | 359,991 |
Loss from operations | (149,807) | (146,732) |
Other (expense) income: | ||
Interest expense | (28,955) | (42,362) |
Interest income | 18,655 | 1,012 |
Other expense, net | (12,255) | (51,274) |
Total other expense, net | (22,555) | (92,624) |
Loss before income taxes | (172,362) | (239,356) |
Provision for income taxes | (1,739) | (985) |
Net loss | $ (174,101) | $ (240,341) |
Net loss per common share - basic (in dollars per share) | $ (1.40) | $ (2.00) |
Net loss per common share - diluted (in dollars per share) | $ (1.40) | $ (2.00) |
Weighted-average common shares used to compute basic net loss per common share (in shares) | 124,111 | 120,393 |
Weighted-average common shares used to compute diluted net loss per common share (in shares) | 124,111 | 120,393 |
Statements of Comprehensive Loss | ||
Net loss | $ (174,101) | $ (240,341) |
Other comprehensive income (loss): | ||
Unrealized gain (loss) on marketable securities | 4,125 | (7,217) |
Foreign currency translation gain | 1,410 | 2,376 |
Defined benefit pension plans, net of tax | (5) | 35 |
Total other comprehensive income (loss) | 5,530 | (4,806) |
Comprehensive loss | (168,571) | (245,147) |
Net product revenues | ||
Revenues: | ||
Total revenues | 276,328 | 186,872 |
Net revenues from collaborations | ||
Revenues: | ||
Total revenues | 36,462 | 25,945 |
Royalty revenue | ||
Revenues: | ||
Total revenues | $ 6,500 | $ 442 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 672,245 | $ 866,394 |
Marketable debt securities | 1,372,574 | 1,297,890 |
Marketable equity securities | 25,856 | 28,122 |
Accounts receivable, net | 219,434 | 237,963 |
Inventory | 131,879 | 128,962 |
Prepaid expenses and other current assets | 119,030 | 132,916 |
Total current assets | 2,541,018 | 2,692,247 |
Property, plant and equipment, net | 523,032 | 523,494 |
Operating lease right-of-use assets | 215,049 | 215,136 |
Restricted investments | 49,388 | 49,390 |
Other assets | 63,453 | 66,092 |
Total assets | 3,391,940 | 3,546,359 |
Current liabilities: | ||
Accounts payable | 62,237 | 98,094 |
Accrued expenses | 508,599 | 545,460 |
Operating lease liability | 43,055 | 41,967 |
Deferred revenue | 35,794 | 42,105 |
Liability related to the sale of future royalties | 23,706 | 40,289 |
Total current liabilities | 673,391 | 767,915 |
Operating lease liability, net of current portion | 259,399 | 261,339 |
Deferred revenue, net of current portion | 191,257 | 193,791 |
Convertible debt | 1,017,887 | 1,016,942 |
Liability related to the sale of future royalties, net of current portion | 1,285,200 | 1,252,015 |
Other liabilities | 224,046 | 212,580 |
Total liabilities | 3,651,180 | 3,704,582 |
Commitments and contingencies (Note 13) | ||
Stockholders’ deficit: | ||
Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of March 31, 2023 and December 31, 2022 | 0 | 0 |
Common stock, $0.01 par value per share, 250,000 shares authorized; 124,241 shares issued and outstanding as of March 31, 2023; 123,925 shares issued and outstanding as of December 31, 2022 | 1,243 | 1,240 |
Additional paid-in capital | 6,522,091 | 6,454,540 |
Accumulated other comprehensive loss | (39,124) | (44,654) |
Accumulated deficit | (6,743,450) | (6,569,349) |
Total stockholders’ deficit | (259,240) | (158,223) |
Total liabilities and stockholders’ deficit | $ 3,391,940 | $ 3,546,359 |